To evaluate the therapeutic potential of S1PR3 inhibition in psoriasis, we administered the S1PR3 antagonist TY (3 mg/kg/day) to mice with IMQ-induced psoriasiform dermatitis for six consecutive days. Here, S1PR3 is linked to Psoriasiform dermatitis.